SCHEMBL1020110

SCHEMBL1020110

Cc1cccc(Cc2nsc(N(C)CCN(C)S(=O)(=O)c3cccs3)n2)c1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
ALDH1A1 P00352 2/20 0.39
HPGD P15428 2/20 0.39
MAPT P10636 3/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
GBA1 P04062 2/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
TSHR P16473 1/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
SQLE Q14534 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1020632 0.90 NPC1 (0.39) POLBSMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL1020403 0.89 GBA1 (0.43) POLBSMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL1021047 0.89 SMN1; SMN2 (0.43) POLBSMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL1020707 0.88 MAPT (0.43) POLBSMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL1019120 0.86 MEN1 (0.42) POLBSMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL1019771 0.84 NPC1 (0.41) POLBSMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL1020588 0.84 NPC1 (0.41) POLBSMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL1019338 0.83 POLB (0.41) POLBSMN1; SMN2ALDH1A1HPGDMAPT
SCHEMBL1018717 0.83 RAB9A (0.44) SMN1; SMN2ALDH1A1HPGDMAPTLMNA
SCHEMBL1018452 0.82 LMNA (0.41) POLBSMN1; SMN2ALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US claimed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP claimed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US claimed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP POLB 2907/4885SMN1; SMN2 8/4885ALDH1A1 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.